论文部分内容阅读
Bristol-Myris-施贵宝（BMS）公司生产的卡托普利已被美国FDA批准用于治疗糖尿病性肾病，并可望于今年L半年申请进入海外市场。临床试验结果表明，卡托普利可使糖尿病性肾病患者发展为晚期肾病或死亡的风险率降低50％，而其对肾脏的保护作用并不依赖于对血压的影响。实验组207
Bristol-Myris-Bristol-Myers-Bristol-Myers Squibb has been approved by the U.S. FDA for the treatment of diabetic nephropathy and is expected to apply for entry overseas in the first half of this year. Clinical trials show that captopril can reduce the risk of developing advanced kidney disease or death in patients with diabetic nephropathy by 50%, whereas its protective effect on the kidneys does not depend on its effect on blood pressure. Experimental group 207